Glomerulonephritis Market Report 2026

Glomerulonephritis Market Overview

• Glomerulonephritis market size has reached to $11.61 billion in 2025 • Expected to grow to $14.66 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Rising Prevalence Of Kidney Disorders Driving The Market Growth • Market Trend: Breakthrough Non-Immunosuppressive Treatment For IgA Nephropathy • North America was the largest region in 2025.

What Is Covered Under Glomerulonephritis Market?

Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys that remove waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure. The main types of glomerulonephritis are acute glomerulonephritis and chronic glomerulonephritis. Acute glomerulonephritis is a sudden kidney inflammation that is often infection-induced and requires prompt treatment to prevent long-term damage. It is diagnosed by various diagnoses such as urine and blood tests, imaging tests, kidney biopsy, and others, and treated with several treatments, including medication, surgery, dialysis, and others. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and others and used by various end-users, including hospitals, specialty clinics, and others.

What Is The Glomerulonephritis Market Growth Forecast?

The glomerulonephritis market size is expected to see steady growth in the next few years. It will grow to $14.66 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advances in renal diagnostics, precision nephrology development, increased chronic kidney disease prevalence, expansion of specialty nephrology care, improved treatment adherence. Major trends in the forecast period include increased focus on early kidney disease diagnosis, rising use of immunosuppressive therapies, growing adoption of biomarker-based testing, expansion of dialysis support services, improved chronic disease management.

Global Glomerulonephritis Market Segmentation

1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis 2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis 3) By Treatment: Medication, Surgery, Dialysis, Other Treatments 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels 5) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome 2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

What Is The Driver Of The Glomerulonephritis Market?

The rising prevalence of kidney disorders is expected to propel the growth of the glomerulonephritis market going forward. Kidney disorders refer to a range of conditions that affect the structure or function of the kidneys, leading to impaired filtration, waste removal, and fluid balance. The rising prevalence of kidney disorders is due to factors such as aging populations, rising rates of chronic diseases such as diabetes and hypertension, and lifestyle choices. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, leading to impaired kidney filtration and function. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization that conducts research and advocacy efforts to improve understanding, prevention, and treatment of kidney diseases, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population and projected to increase to 7.61 million people by 2033. Therefore, the rising prevalence of kidney disorders will drive the growth of the glomerulonephritis industry.

Key Players In The Global Glomerulonephritis Market

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

Global Glomerulonephritis Market Trends and Insights

Major companies operating in the glomerulonephritis market are focusing on developing advanced non-immunosuppressive treatments to address unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are therapies that do not weaken or suppress the immune system, aiming to treat conditions without compromising immune function. For instance, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, introduced FILSPARI (sparsentan), approved by the Food and Drug Administration (FDA) for treating IgA nephropathy, a kidney disease. The drug is the only non-immunosuppressive treatment shown to significantly slow kidney function decline in these patients. FILSPARI’s approval marks a major breakthrough in the treatment of IgA nephropathy, which is the most common type of primary glomerulonephritis. The therapy offers a new option for patients who previously had limited choices. This approval highlights Travere's commitment to improving patient outcomes in kidney disease.

What Are Latest Mergers And Acquisitions In The Glomerulonephritis Market?

In May 2023, Rona Therapeutics Inc., a China-based biopharmaceutical company, partnered with Keymed Biosciences Inc. to address the urgent need for new medicines. This partnership aims to develop first-in-class siRNA therapeutics for Glomerulonephritis. Keymed Biosciences Inc. is a China-based biotechnology company that develops treatments for glomerulonephritis.

Regional Outlook

North America was the largest region in the glomerulonephritis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glomerulonephritis Market?

The glomerulonephritis market consists of revenues earned by entities by providing services such as immunosuppressive therapy, blood pressure control, and kidney transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The glomerulonephritis market also includes sales of complement-level test kits, urine protein test kits, and medication. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glomerulonephritis Market Report 2026?

The glomerulonephritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glomerulonephritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.